#United States #Palo Alto #Biomedical Research #CellBio Scientific #Charles Miller

Charles Miller Takes the Helm at CellBio Scientific

CellBio Scientific, a recognized leader in providing advanced tools and services for biomedical research, has recently appointed Charles Miller as its first Chief Executive Officer, effective March 31, 2025. This significant move is aimed at steering the company towards growth following its recent strategic acquisitions.

In his new role, Miller is tasked with leveraging his extensive experience to expand the company’s market reach and enhance overall customer value within the life sciences sector. With a solid background of over 15 years in drug discovery and diagnostics, he aims to make a substantial impact on both the organization and the broader scientific community.

Miller has previously held key positions at The Jackson Laboratory and Elephas Biosciences, where he was instrumental in leading global commercial operations. He effectively managed teams that generated revenues surpassing $500 million, and he successfully built and expanded brands in life sciences and drug discovery across more than 70 countries. His strong track record highlights a capacity for transforming organizations and promoting sustainable growth.

In a statement reflecting his commitment to CellBio Scientific, Miller expressed, "I'm honored to join CellBio Scientific at such a pivotal moment in its journey. The opportunity to unify exceptional teams, build on a foundation of scientific excellence, and scale solutions that truly advance human health is both exciting and urgent. I look forward to working closely with our customers, partners, and employees to drive innovation, unlock new markets, and shape the future of drug discovery and human health."

Miller holds a BS and PhD in biomedical sciences from the University of Michigan and Michigan State University, respectively, along with an MBA from Yale. His management philosophy emphasizes clarity, resilience, and fostering high-performance cultures that deliver tangible results.

Mark Hilderbrand, Chair of the Board of Directors at CellBio, emphasized the strategic fit of Miller for the role, stating, “Charles is exactly the leader we need to drive CellBio Scientific into its next phase of growth. His experience scaling global life sciences platforms and his insightful vision for innovation make him uniquely poised to lead this organization.” His appointment signals the company’s readiness to accelerate execution on its strategic objectives, expand into new verticals, and build a robust portfolio of drug discovery tools and services.

About CellBio Scientific
Formed through the merger of System Biosciences (SBI) and Acepix Biosciences, CellBio Scientific is a premier provider specializing in life science tools, research services, and clinical solutions that advance the frontiers of biomedical discovery. The company boasts a comprehensive portfolio that includes biospecimens, spatial biology, extracellular vesicle technologies, gene delivery systems, and much more. With a strong dedication to scientific excellence and innovation, the company empowers researchers and biopharmaceutical partners in driving breakthroughs in human health.

As CellBio Scientific embarks on this exciting new chapter under Miller’s leadership, stakeholders and employees alike are keenly anticipating the innovative directions and growth opportunities that lie ahead.